Skip to main content

Liver cancer (HCC) – symptoms, diagnosis, treatment

Advertisement

What is meant by the term liver cancer (hepatocellular carcinoma)?

The liver, as the largest gland in the human body, performs numerous important functions. These include the production of essential proteins, the utilisation of nutrients, the production of bile, and the breakdown and excretion of metabolic waste products, medicines and toxins. If certain abnormal changes take hold in the cells of a part of this vital organ, liver cancer can develop – that is, a malignant tumour of the liver. This type of cancer also frequently metastasises to the lungs and bones.

Experts distinguish between primary liver cancer, which develops directly from the cells of the liver, and secondary liver cancer, in which the tumour forms in the liver but not from its own cells; rather, it arises from cells of other tissues that continue to grow in the liver (metastases). This can be the case, for example, with bowel cancer, stomach cancer or breast cancer, when the ‘primary cancer’ is at an advanced stage. Sometimes it is not possible to determine which underlying condition caused these metastases. In this case, the condition is referred to as ‘cancer of unknown primary’ (CUP syndrome, cancer of unknown origin).

Primary liver cancer is divided into hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CCC). The latter originates in the bile ducts and then invades the liver.

Hepatocellular carcinoma is the fifth most common malignant tumour, with its incidence having doubled over the last 20 years. Experts attribute this primarily to the higher rate of new hepatitis C cases.

Men are three times more likely to be affected by HCC than women.

Liver cancer: causes and risk factors

As regards the causes of liver cancer, these are not yet fully understood. However, it is known that cirrhosis of the liver is the main risk factor for the development of malignant hepatocellular carcinoma. This involves the chronic destruction of healthy liver tissue, after which the liver regenerates but develops an abnormal tissue structure with nodular changes. In addition, a vast amount of connective tissue forms. This process is referred to as fibrosis. It disrupts blood flow to the liver, causing blood to back up in the area of the portal vein in front of the liver (portal hypertension).

The main causes of liver cirrhosis are chronic alcohol abuse and chronic viral infections (hepatitis B and C). Other causes of liver cirrhosis and liver cancer include haemochromatosis (a congenital disorder of iron metabolism), the mould Aspergillus flavus, and the hereditary condition alpha-1 antitrypsin deficiency. Prolonged exposure to the fat- and oil-soluble solvent carbon tetrachloride, which is used in the manufacture of plant protection products, also significantly increases the risk of developing liver cancer.

Other possible causes of primary liver cancer are of a molecular-genetic nature. For example, it is known that in around 60 per cent of patients, the tumour suppressor gene FHIT is defective. This inhibits the production of numerous proteins, leading to uncontrolled cell growth.

In addition, long-term abuse of androgens (for example, by bodybuilders) can increase the risk of developing HCC.

As regards the causes of cholangiocellular carcinoma, the following conditions are considered risk factors:

  • Bile duct stones
  • rare chronic inflammations of the bile ducts
  • benign tumours of the bile ducts, which may become malignant
  • Cysts in the bile duct
  • chronic parasitic liver diseases, which occur mainly in Asia (for example, liver fluke)

Hepatocellular carcinoma: symptoms

Liver cancer rarely causes any symptoms at the onset of the disease, meaning that those affected do not notice anything at first. The first signs, which are usually non-specific, generally only appear at an advanced stage of the disease – by which time it is often too late for a complete cure.

The following symptoms may occur:

Non-specific symptoms:

  • unintentional weight loss
  • Loss of appetite
  • Decreased energy levels
  • Upper abdominal pain
  • Fever
  • Night sweats

Other symptoms, which are usually the result of increased tumour growth, do not appear until later. These include:

  • Jaundice: yellowing of the eyes, and later also of the skin
  • Itching
  • Pain on pressure in the upper right abdomen
  • Ascites: This is caused by a disturbance in protein metabolism, leading to excessive fluid accumulation in the abdominal cavity and an increase in abdominal girth
  • A palpable tumour in the upper right abdomen
  • Dark urine and pale, discoloured stools

Diagnosis of liver cancer

Diagnosis begins with taking a medical history (anamnesis), during which the doctor will also ask whether the patient works in the medical profession, has travelled abroad or is employed overseas. Questions are also asked about frequently changing sexual partners without adequate protection against sexually transmitted infections, as well as any previously diagnosed liver cirrhosis.

This is followed by a physical examination, during which the abdomen is palpated and percussed. A blood sample is also taken and analysed in the laboratory for all key parameters, including a complete blood count and coagulation tests. (Anaemia, impaired liver function and elevated cholestasis levels can provide initial indications.) Furthermore, the tumour markers AFP and Ca 19-9, which are elevated in cases of liver cancer, amongst other conditions, are analysed.

An ultrasound scan can visualise a large liver tumour. If, following these investigations, there is reasonable suspicion of liver cancer, computed tomography and/or magnetic resonance imaging of the abdomen are used, as well as chest X-rays and a bone scan to diagnose metastases, a tumour biopsy and, where necessary, angiography to prepare for surgery or in cases of an unclear diagnosis. In the case of liver cancer, a definitive diagnosis can only be confirmed by a biopsy via puncture or by laparoscopy.

As regards further diagnostic investigations in cases of suspected metastases, a gastroscopy and a colonoscopy are usually carried out, as these types of cancer, as well as pancreatic cancer, most commonly metastasise to the liver first.

If cholangiocellular carcinoma is suspected, an initial ultrasound scan of the upper gastrointestinal tract is carried out, followed by an endoscopic examination of the bile ducts.

Treatment of liver cancer

Treatment for hepatocellular carcinoma depends on the size, extent and location of the tumour. The patient’s general condition also plays a major role. The so-called Karnofsky Index can be used to determine which treatment is most suitable for the patient. To make a final decision, it is also important to assess the condition of the liver, whether cirrhosis is present, and whether synthetic or detoxification functions are impaired.

Surgery: If liver function is still well preserved and the tumour is easily accessible, surgery is the treatment of choice. In the case of metastases, the primary tumour must also be treated, and chemotherapy and/or radiotherapy may be required.

Liver transplant: If there is extensive cirrhosis of the liver, a liver transplant offers a better chance of success than simply removing the tumour. This requires the patient to be in good general health with no serious underlying conditions. Following the complete removal of the liver, a donor liver is transplanted; after the transplant, the patient must continue to take immunosuppressant medication to prevent the organ from being rejected.

Radiofrequency ablation (RFA, RFTA, RITA): Under ultrasound or CT guidance, a probe is inserted into the tumour. Radiofrequency waves are delivered via this probe to heat the tumour tissue, thereby ‘cooking’ the tumour.  

Microwave ablation (MWA): This is a procedure similar to RFA, but microwaves are delivered to the tumour instead of radiofrequency waves. This allows even higher temperatures to be generated. This method is primarily used for HCC lesions located close to large, well-perfused blood vessels.

Transarterial chemoembolisation (TACE): This combines the principles of embolisation and chemotherapy. A catheter is guided from the groin to the hepatic artery, and through this catheter small plastic particles are injected into the vessel supplying the tumour until the vessel is blocked and the blood supply to the tumour is cut off. In addition, a chemotherapeutic agent is injected through the catheter. These procedures cause the cancer cells to die, slow down tumour growth and improve survival. Chemoembolisation is also used as a bridging treatment prior to a liver transplant.

Transarterial radioembolisation (TARE): This is a local radiotherapy treatment for liver tumours, which utilises the arteries supplying the liver to place the radiation source directly at the tumour site. Tiny beads containing a radioactive substance with a very short range are delivered directly into the liver vessels via a catheter. The procedure is used in patients with liver cancer confined to the liver that cannot be treated either surgically or by local ablation. The advantage of this method over TACE is that it can usually be carried out in a single session and, in some circumstances, may also be used in patients with a blocked portal vein or where HCC lesions have invaded blood vessels.

External radiotherapy: There are two methods:

  • Stereotactic Body Radiotherapy (SBRT): This is a form of external beam radiotherapy used for locally confined liver carcinomas that cannot be treated either surgically or with minimally invasive local procedures. This technique allows tumours to be irradiated with great precision, whilst sparing healthy tissue and neighbouring organs. Due to its high local response rate, SBRT is also an alternative for bridging the period until a liver transplant.
  • Proton therapy: In this procedure, the tumour is precisely targeted with alpha radiation (protons), allowing tumours to be treated from the outside in a more targeted and gentler manner than with conventional radiotherapy methods, which use gamma rays or electrons.
Foto:SirichaiPuangsuwan/Shutterstock

Drug treatment (systemic therapy): This involves administering drugs in the form of tablets or infusions, which are then distributed throughout the body. Classic active substances include chemotherapeutic agents or cytostatic drugs, which primarily target fast-growing cells such as cancer cells. However, healthy cells may also be affected in the process. Chemotherapy is very rarely used for liver cancer because it has generally not proved effective against these tumours. However, they do have their place in localised therapies, as the active substance is delivered directly to the tumour, making it more effective and minimising unwanted side effects on healthy tissue.
Instead, so-called targeted therapies, which act very specifically on cancer cells, are often used to treat HCC. These include tyrosine kinase inhibitors, immunotherapies and antibodies. They can also be used in the advanced stages of the disease, when the cancer can no longer be effectively treated with local therapies.

  • Tyrosine kinase inhibitors: These are active substances that penetrate the interior of cancer cells, where they usually inhibit several different types of tyrosine kinases simultaneously; these kinases enable the uncontrolled growth of tumour cells. This can halt tumour growth, at least temporarily. Please note: Some tyrosine kinase inhibitors can cause serious side effects, and normal liver function and a good general state of health in the patient are prerequisites for treatment with these medicines.
  • Antibody therapies: Antibodies do not directly influence the immune system, but – similar to tyrosine kinase inhibitors – bind to signalling structures, thereby preventing the growth of blood vessels within the tumour. The cancer cells can then no longer be adequately supplied with nutrients and die off.
  • Immunotherapies: These work by activating the body’s own immune system to fight the cancer cells, prompting it to recognise and destroy them. Please note: Some patients cannot receive immunotherapy. These include, for example, immunosuppressed patients or those with known autoimmune diseases.  

Palliative therapies: When a cure is no longer possible, so-called symptomatic, supportive therapies are used to treat pain and other symptoms of the cancer.

Hepatocellular carcinoma: Follow-up care and prevention

As part of follow-up care, it is necessary to check certain tumour markers every six months, and to carry out a physical examination and an ultrasound scan to detect a recurrence (the tumour returning).

As regards the prevention of liver cancer, vaccination against hepatitis B reduces the likelihood of contracting hepatitis, particularly in young children and at-risk adults who are drug-dependent or work in the medical sector (where there is a risk of infection). In addition, responsible alcohol consumption reduces the likelihood of developing cirrhosis of the liver – which is, after all, the main risk factor for liver cancer.

  • Author

    Gernot Hofer

More on this topic
Hormones

Low testosterone in men: symptoms, causes and treatment

Fatigue, a reduced sex drive, and a lack of energy: these symptoms can have many causes. One possible explanation is a testosterone deficiency. However, it is not possible to determine whether testosterone levels are actually too low based solely on the symptoms or on a single blood test result.

Men's health
Men's health

PSA level: What does it mean, and when is it too high?




The PSA level is one of the best-known laboratory test results relating to the prostate. Many men come across it for the first time during a screening examination or when having symptoms investigated. An abnormal result often raises questions: Is this already a sign of prostate cancer? What levels are considered normal?

Prostate
Pollen allergy

The right diet for hay fever

Anyone suffering from hay fever should pay particular attention to their diet so as not to make the symptoms any worse.

Nutrition
Urology

Prostate health: What men need to know

The prostate is a gland in a man’s body that is only the size of a chestnut, but it plays a crucial role in well-being, urinary function and male sexuality. Benign enlargement and prostate cancer become more common in older age.

Prostate